Abstract:Using a scalable method for fabricating solid drug nanoparticles (SDNs), SDNs in fixed combination of the hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX) are consistently produced. These SDNs demonstrated enhanced ocular permeation and sustained intraocular pressure reduction, indicating their effectiveness for glaucoma therapy. Efficient topical drug delivery remains a significant challenge in glaucoma management. Although nanoparticle formulations offer considerable promise, their complex preparation processes, co‐delivery issues, and batch consistency have hindered their potential. A scalable fabrication strategy is developed here for preparing solid drug nanoparticles (SDNs) with enhanced drug delivery efficiency. Utilizing hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX), uniform fixed combination BM/BX SDNs are fabricated through a continuous process, improving batch‐to‐batch consistency for combined glaucoma treatment. With trehalose being used as a lyoprotectant, BM/BX SDNs can be stored as dry powder and easily reconstituted in phosphate buffered saline. Importantly, reconstituted BM/BX SDNs form clear, homogenous solutions, and exhibit negligible cytotoxicity and irritation, making them well‐suited for topical administration as eyedrops. Ex vivo and in vivo studies demonstrated that topically applied BM/BX SDNs permeate through the cornea significantly (about two fold to three fold) compared to their hydrophilic counterparts, i.e., brimonidine tartrate, and betaxolol hydrogen chloride. Notably, BM/BX SDNs displayed consistent intraocular pressure lowering effects in vivo in both normotensive rats and glaucoma mice. Collectively, this study demonstrates the potential of the scalable fabrication strategy and the resultant BM/BX SDNs for improving glaucoma management through eyedrops.

Core-shell lipid-polymer nanoparticles as a promising ocular drug delivery system to treat glaucoma

Recent Advances and Prospects for Lipid-Based Nanoparticles As Drug Carriers in the Treatment of Human Retinal Diseases

Nanoparticles in the Ocular Drug Delivery

Active Trans-Corneal Drug Delivery with Ocular Adhesive Micelles for Efficient Glaucoma Therapy.

Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy

Revamping the corneal permeability and antiglaucoma therapeutic potential of brinzolamide using transniosomes: optimization, in vitro and preclinical evaluation

PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers

Phospholipid free nano-vesicles of Brinzolamide Biopolymer Ocular Insert; design, in vitro and in vivo evaluation

Enhancement of therapeutic efficacy of Brinzolamide for Glaucoma by nanocrystallization and tyloxapol addition

Anti-oxidative mesoporous polydopamine-based hypotensive nano-eyedrop for improved glaucoma management

Self-assembled latanoprost loaded soluplus nanomicelles as an ophthalmic drug delivery system for the management of glaucoma

Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment

Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation

A one-platform comparison study of brinzolamide-loaded liposomes, niosomes, transfersomes, and transniosomes for better management of glaucoma

Uptake of metabolism of norepinephrine in isolated perfused fetal, newborn and adult rabbit lungs.

A Potential New Therapeutic System for Glaucoma: Solid Lipid Nanoparticles Containing Methazolamide

Dendritic Oligoethylenimine Decorated Liposome with Augmented Corneal Retention and Permeation for Efficient Topical Delivery of Antiglaucoma Drugs

Polymeric Propranolol Nanoparticles for Intraocular Delivery: Formulation, Characterization, and Vitreous Pharmacokinetics

Micro-interaction of montmorillonite-loaded nanoparticles with mucin promotes retention of betaxolol hydrochloride on the ocular surface and the tear film microenvironment

A Promising 'Single' and 'Dual' Drug-Nanocomposite Enriched Contact Lens for the Management of Glaucoma in Response to Tear Fluid Enzyme

Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma